Keros Therapeutics, Inc.
Develops protein therapeutics for disorders linked to TGF-β signaling.
KROS | US
Overview
Corporate Details
- ISIN(s):
- US4923271013
- LEI:
- Country:
- United States of America
- Address:
- 1050 WALTHAM STREET, SUITE 302, 2421 LEXINGTON
- Website:
- https://www.kerostx.com/
Description
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics. The company develops engineered protein therapeutics designed to address a wide range of disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) superfamily of proteins. Its approach aims to selectively and potently modulate these signaling pathways to treat the underlying causes of various hematological and musculoskeletal diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
|
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB
Full Filing History RestrictedAccess to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset. |
|||||
Automate Your Workflow. Get a real-time feed of all Keros Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Keros Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Keros Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
